TIGIT

End of road sign on street
Biotech

GSK axes $625M TIGIT drug as midphase data disappoint

GSK and its partner iTeos Therapeutics took the action after an assessment of the effect on progression-free survival fell short of expectations.
Nick Paul Taylor May 13, 2025 9:44am
stop shut down close end button

BeiGene drops TIGIT drug over poor phase 3 lung cancer prospects

Apr 3, 2025 8:05am
The Top Line

What were the biggest clinical trial flops of 2024?

Feb 21, 2025 9:00am
arrow miss target fail attempt try

Merck discontinues development of 2 late-stage cancer assets

Dec 16, 2024 5:39pm
pipeline new drugs pipes faucet

iTeos drops one of 3 clinical assets from pipeline

Dec 12, 2024 3:10pm
failure crash no fail rocket cancelled end

Roche's TIGIT prospect fails another phase 3 lung cancer test

Nov 26, 2024 4:11am